[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Chemoimmunotherapy With Obinutuzumab, Ifosfamide, Carboplatin and Etoposide (O-ICE) in Children, Adolescents and Young Adults With Recurrent Refractory CD20+ Mature B-NHL


Description

The purpose of this study is to determine the safety of administering obinutuzumab as a single agent alone and in combination with ifosfamide, carboplatin, and etoposide (ICE) chemotherapy and determine the response rate of this treatment for children, adolescents and young adults (CAYA) with relapsed CD20 positive B-cell Non-Hodgkin Lymphoma (B-NHL).

Trial Eligibility

Inclusion Criteria: * Patients in first relapse or primary induction failure CD20 positive B-cell leukemia/lymphoma including: * Diffuse Large B-Cell Lymphoma * Burkitt Lymphoma * High Grade B-cell Lymphoma: Not Otherwise Specified (NOS) * Primary mediastinal B-cell lymphoma (PMBL) * CD20+ B-lymphoblastic lymphoma * Follicular lymphoma, Grade III * Karnofsky ≥ 60% for patients \> 16 years of age and * Lansky ≥ 60 for patients ≤ 16 years of age. * Myelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study. * Patients may not have received prior therapy with obinutuzumab (GA101) * Radiation Therapy (XRT): Date of receiving prior XRT must be \> 2 weeks for local palliative XRT (small port); \> 6 months must have elapsed if prior craniospinal XRT or if \> 50% radiation of pelvis; \> 6 weeks must have elapsed if other substantial bone marrow radiation. * Steroids: Patients may have received prior steroid treatment, but not started greater than 7 days prior to initiation of protocol therapy. * Adequate organ function. Exclusion Criteria: * Patients with newly diagnosed, previously untreated B-NHL. * Known congenital or acquired immune deficiency. * Prior solid organ transplantation. * Prior allogeneic stem cell transplant within 60 days or active acute Graft-vs-Host-Disease (GVHD) grade 3 or higher. * History of grade 4 anaphylactic reactions to humanized or murine monoclonal antibodies * Uncontrolled hepatitis B and/or C infection

Study Info

Organization

New York Medical College


Primary Outcome

Safety as assessed by adverse reactions and events


Outcome Timeframe 1 month

NCTID NCT02393157

Phases PHASE2

Primary Purpose TREATMENT

Start Date 2015-08-21

Completion Date 2024-12

Enrollment Target 25

Interventions

DRUG Obinutuzumab

DRUG Liposomal ARA-C

DRUG Ifosfamide

DRUG Carboplatin

DRUG Etoposide

Locations Recruiting

New York Medical College

United States, New York, Valhalla


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your T-Cell Lymphoma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.